Billionaires Holding ENZN

BILLIONAIRE ALLOCATION SHARES OWNED (M) % CO AVG. COST RETURN

FUNDAMENTALS

  • 1.65
    PE

  • 42.06
    Yield

  • 44.1M
    Shares Outstanding

  • 47.7M
    Market Cap

News & Insights

ABOUT

ENZN

Enzon Pharmaceuticals, Inc. engages in licensing drug products. Its marketed drug products include PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular (wet) age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and Crohn’s disease. Th...

09 Jul '15

ENZN > STOCK OF THE DAY

Enzon Pharmaceuticals Inc is +9.40% after announcing a special cash dividend.

NEWS

BRIEF-Berkshire Hathaway buys about 824,000 shares of Phillips 66

READ MORE